Anti-Dibromotyrosine antibody [9F12] (ab240911)
Key features and details
- Mouse monoclonal [9F12] to Dibromotyrosine
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG1
Overview
-
Product name
Anti-Dibromotyrosine antibody [9F12]
See all Dibromotyrosine primary antibodies -
Description
Mouse monoclonal [9F12] to Dibromotyrosine -
Host species
Mouse -
Specificity
Does not cross-react with Nitrotyrosine. -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human -
Immunogen
Chemical/ Small Molecule corresponding to Dibromotyrosine conjugated to keyhole limpet haemocyanin.
-
Positive control
- WB: Dibromotyrosine-BSA; HeLa cells treated with hydrogen peroxide.
-
General notes
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.09% Sodium azide
Constituents: PBS, 50% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Purity
Protein G purified -
Purification notes
Purified from TCS. -
Clonality
Monoclonal -
Clone number
9F12 -
Isotype
IgG1
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab240911 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | 1/1000. |
Target
-
Alternative names
- 3,5-Dibromo-tyrosine antibody
- 3,5-dibromotyrosine antibody
- Dibromo-tyrosine antibody
- DiBrY antibody
Images
-
All lanes : 2 hours at RT at 1/1000 dilution
Lane 1 : HeLa (human epithelial cell line from cervix adenocarcinoma) cell lysate
Lane 2 : Hydrogen peroxidase treated HeLa cell lysate
Lysates/proteins at 12 µg per lane.
Secondary
All lanes : Goat Anti-Mouse IgG-HRP for 60 minutes at RT at 1/2000 dilution
Developed using the ECL technique.
Exposure time: 5 minutesBlock: 5% Skimmed milk in TBST.
-
All lanes : Anti-Dibromotyrosine antibody [9F12] (ab240911) at 1/1000 dilution (2 hours at RT)
Lane 1 : BSA
Lane 2 : Nitrosylated-BSA
Lane 3 : Dibromotyrosine-BSA
Lysates/proteins at 1 µg per lane.
Secondary
Lanes 1-2 : Goat Anti-Mouse IgG-HRP for 60 minutes at RT. at 1/2000 dilution
Lane 3 : Goat Anti-Mouse IgG-HRP for 60 minutes at RT at 1/2000 dilution
Developed using the ECL technique.
Exposure time: 5 minutesBlock: 5% Skimmed milk in TBST.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
References (0)
ab240911 has not yet been referenced specifically in any publications.